logo

Ionis Pharmaceuticals Inc (IONS)



Trade IONS now with
  Date
  Headline
11/9/2022 7:07:10 AM Ionis Pharmaceuticals Q3 Net Loss Narrows To $47 Mln From $82 Mln Last Year
11/7/2022 7:08:44 AM Ionis Presents Positive Phase 2 Data In Patients With IgA Nephropathy At ASN Kidney Week 2022
11/4/2022 7:16:45 AM Ionis Pharma Presents Positive Phase 2b Data From RE-THINC ESRD Study Of Fesomersen In Patients On Hemodialysis At ASN
10/12/2022 7:06:49 AM Ionis Pharma Unveils Plan For New Manufacturing Facility In Oceanside, Calif.
9/23/2022 2:28:47 AM Ionis Pharma Says Phase 2bSOLANO Study For Patients With Hypercholesterolemia Meets Primary Endpoint
9/7/2022 2:33:47 AM Ionis Presents Positive Results From Phase 3 NEURO-TTRansform Study On Amyloidosis
7/26/2022 7:33:02 AM Ionis Says FDA Accepts NDA, Grants Priority Review Of Tofersen For Rare, Genetic Form Of ALS
7/11/2022 7:11:21 AM Ionis Pharma: Roche To Advance IONIS-FB-LRx Into Phase 3 Study In Patients With Immunoglobulin A Nephropathy
6/25/2022 9:58:38 AM Ionis Presents Positive Phase 2b Data For Chronic Hepatitis B Treatment At EASL International Liver Congress
6/3/2022 5:23:01 AM Ionis :Biogen Says Results From Phase 3 Study And Open-label Extension Of Tofersen Shows Clinical Benefit In SOD1-ALS
4/4/2022 12:20:51 AM Ionis Presents Positive Data For ETESIAN Phase 2b Study Of Antisense Medicine Targeting PCSK9 At 2022 ACC